GE Healthcare CEO Succession: John Flannery In, John Dineen Moves On
This article was originally published in The Gray Sheet
Executive Summary
The lead GE business development executive John Flannery is taking over the top spot of the firm’s health care business, replacing John Dineen, who is leaving GE after seven years running Healthcare and 28 years at the company.
You may also be interested in...
Medtech Innovation From An Industrial Perspective: An Interview With GE Healthcare’s John Dineen
Because the GE brand is so ubiquitous, visible on everything from household appliances to airplane engines, it’s easy to assume a familiarity with GE and, in particular, with what its health care business is all about. But this interview with John Dineen, President and CEO of GE Healthcare and GE Medical Systems Information Technologies Inc. makes clear that GE’s world view is anything but familiar and stands in striking contrast to that of most other medical technology companies.
Japan Grants Global-First Approval To Zolbetuximab With 15 New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.